EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pan-Immune-Inflammation Value as a Predictor of Long-Term Outcomes in Patients with Urothelial Carcinoma of the Bladder: A Pilot Study

Ali Erhan Eren, Asim Armagan Aydin iD, Eren Erdi Aksaray iD, Arda Durak iD, Ahmet Unlu iD, Mahmut Ekrem Islamoglu iD, Banu Ozturk, Mustafa Yildiz

Current Oncology · 24.09.2025 · 32 (10) · 534

DOI: 10.3390/curroncol32100534 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, online erschienen am 24.09.2025. Verfasst von Ali Erhan Eren und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of Health Sciences Antalya Education and Research Hospital, Antalya 07100, Turkey. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Non-Muscle Invasive Bladder Neoplasms, Inflammation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Urothelial carcinoma of the bladder (UCB) demonstrates considerable heterogeneity, with markedly varying outcomes between non–muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). The pan-immune-inflammation value (PIV), derived from routine hematological parameters, has emerged as a novel biomarker reflecting systemic inflammation and immune dysregulation. This pilot, exploratory analysis evaluated the prognostic relevance of the PIV in UCB and contextualized PIV against other inflammation-based indices.

Methods

We retrospectively analyzed 119 patients with histologically confirmed UCB who were treated between 2019 and 2024. PIV was calculated as (neutrophils × platelets × monocytes) ÷ lymphocytes. Additional indices included the NLR, SII, SIRI, and PLR. Progression-free survival (PFS) and overall survival (OS) were estimated using Kaplan–Meier analysis, and prognostic factors were assessed using Cox regression.

Results

Among 119 patients (median age, 72 years; 88% male), 68 were diagnosed with NMIBC and 51 with MIBC. Elevated PIV levels were significantly associated with NMIBC progression to MIBC (p = 0.028) and strongly correlated with NLR, SII, SIRI, and PLR. Patients with high PIV exhibited shorter OS (24 vs. 45 months) and PFS (20 vs. 35 months) than those with low patients (p < 0.001). Although the prognostic value was evident in the univariate analyses, PIV did not retain significance in multivariate models.

Conclusion

Elevated PIV levels predict adverse survival outcomes and progression in UCB, underscoring its potential as a cost-effective and accessible biomarker for risk stratification. Prospective validation in larger cohorts is warranted to confirm its role in personalized patient management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsCarcinoma, Transitional CellNon-Muscle Invasive Bladder NeoplasmsInflammationPilot ProjectsPrognosisProgression-Free SurvivalDisease ProgressionKaplan-Meier EstimateRetrospective StudiesFollow-Up StudiesHumansMaleFemaleMiddle AgedAgedAged, 80 and over

Stichwörter der Autor:innen

biomarkerbladder cancermuscle invasivenon-muscle invasivepan-immune-inflammation valueprognosissurvivalurothelial carcinoma

Autor:innen und Institutionen

  • Department of Urology, University of Health Sciences Antalya Education and Research Hospital, Antalya 07100, Turkey.
  • Department of Clinical Oncology, University of Health Sciences Antalya Education and Research Hospital, Antalya 07100, Turkey.

ORCID-Profile: Asim Armagan Aydin, Eren Erdi Aksaray, Arda Durak, Ahmet Unlu, Mahmut Ekrem Islamoglu

Zitieren

APA

Eren, A. E., Aydin, A. A., Aksaray, E. E., Durak, A., Unlu, A., Islamoglu, M. E., Ozturk, B., & Yildiz, M. (2025). Pan-Immune-Inflammation Value as a Predictor of Long-Term Outcomes in Patients with Urothelial Carcinoma of the Bladder: A Pilot Study. Current Oncology, 32(10), 534. https://doi.org/10.3390/curroncol32100534

Vancouver

Eren AE, Aydin AA, Aksaray EE, Durak A, Unlu A, Islamoglu ME, et al. Pan-Immune-Inflammation Value as a Predictor of Long-Term Outcomes in Patients with Urothelial Carcinoma of the Bladder: A Pilot Study. Current Oncology. 2025;32(10):534. doi:10.3390/curroncol32100534

BibTeX
@article{Eren2025,
  author = {Eren, Ali Erhan and Aydin, Asim Armagan and Aksaray, Eren Erdi and Durak, Arda and Unlu, Ahmet and Islamoglu, Mahmut Ekrem and Ozturk, Banu and Yildiz, Mustafa},
  title = {Pan-Immune-Inflammation Value as a Predictor of Long-Term Outcomes in Patients with Urothelial Carcinoma of the Bladder: A Pilot Study},
  journal = {Current Oncology},
  year = {2025},
  volume = {32},
  number = {10},
  pages = {534},
  doi = {10.3390/curroncol32100534}
}
Kostenlos starten →